CELL INTELLIGENCE · 肿瘤细胞治疗研究

CELLIN 肿瘤细胞治疗研究

← 返回

循环 NK 细胞对接受免疫检查点抑制剂治疗的非小细胞肺癌患者的预后价值：与肌少症的相关性

英文原题：Circulating Natural Killer Cells as Prognostic Value for Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: Correlation with Sarcopenia.

查看英文原题

Circulating Natural Killer Cells as Prognostic Value for Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: Correlation with Sarcopenia.

PubMed 2023/07/12（内容时间） Cancers (Basel) Q2 · IF 4.8（JCR 2025）

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

技术：NK 细胞非小细胞肺癌地区：欧洲
登录后收藏与关注 全文解读登录并开通会员后使用加入对比登录并开通会员后使用

研究概要

外周 NK 细胞可能是一种无创且有用的工具，可用于预测 NSCLC 患者的 ICI 治疗反应，而低 NK 细胞水平与肌肉减少症的关联在临床评估中值得更多关注。

研究思路结论见上方概要

背景

免疫检查点抑制剂（ICIs）已经彻底改变了肿瘤的治疗。自然杀伤（NK）细胞在癌症免疫监视中可发挥重要作用。这项前瞻性观察性研究的目的是分析接受ICIs治疗的晚期非小细胞肺癌（NSCLC）患者的外周血单个核细胞（PBMCs），以确定更好生存结局的预测因素。

方法

纳入47例IV期NSCLC患者。患者在ICIs治疗后接受基线（T 0）和纵向（T 1）评估。采用流式细胞术分析外周免疫血细胞计数。

结果

疾病控制（DC）患者的CD3-CD56+NK细胞基线水平高于疾病进展（PD）患者（127 cells/ L vs. 27.8 cells/ L，p < 0.001）。较低的NK细胞值是较短总生存期（OS）（HR 0.992；95% CI 0.987-0.997，p < 0.001）和无进展生存期（PFS）（HR 0.988；95% CI 0.981-0.994，p < 0.001）的独立预后因素。在纵向评估中，DC组的CD3-CD56+NK细胞（138.1 cells/ L vs. 127 cells/ L，p = 0.025）和CD56 bright NK细胞（27.4 cells/ L vs. 18.1 cells/ L，p = 0.034）显著增加。最后，与无肌肉减少症的患者相比，肌肉减少症患者的CD3-CD56+NK细胞（28.3 cells/ L vs. 114.6 cells/ L，p = 0.004）和CD56 dim NK细胞（13.2 cells/ L vs. 89.4 cells/ L，p < 0.001）值较低。

展开英文摘要原文
BACKGROUND

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of tumors. Natural killer (NK) cells can play an important role in cancer immune surveillance. The aim of this prospective observational study was to analyze peripheral blood mononuclear cells (PBMCs) in patients with advanced non-small-cell lung cancer (NSCLC) receiving ICIs in order to identify predictive factors for better survival outcomes.

METHODS

Forty-seven stage IV NSCLC patients were enrolled. Patients underwent baseline (T 0 ) and longitudinal (T 1 ) evaluations after ICIs. Peripheral immune blood cell counts were analyzed using flow cytometry.

RESULTS

Basal levels of CD3 - CD56 + NK cells were higher in patients with controlled disease (DC) compared to progression disease (PD) patients (127 cells/ L vs. 27.8 cells/ L, p < 0.001). Lower NK cell values were independent prognostic factors for shorter overall survival (OS) (HR 0.992; 95% CI 0.987-0.997, p < 0.001) and progression-free survival (PFS) (HR 0.988; 95% CI 0.981-0.994, p < 0.001). During the longitudinal evaluation, CD3 - CD56 + NK cells (138.1 cells/ L vs. 127 cells/ L, p = 0.025) and CD56 bright NK cells (27.4 cells/ L vs. 18.1 cells/ L, p = 0.034) significantly increased in the DC group. Finally, lower values of CD3 - CD56 + NK cells (28.3 cells/ L vs. 114.6 cells/ L, p = 0.004) and CD56 dim NK cells (13.2 cells/ L vs. 89.4 cells/ L, p < 0.001) were found in sarcopenic patients compared to patients without sarcopenia.

CONCLUSIONS

Peripheral NK cells could represent a non-invasive and useful tool to predict ICI therapy response in NSCLC patients, and the association of low NK cell levels with sarcopenia deserves even more attention in clinical evaluation.

论文信息

作者
Tenuta M、Pandozzi C、Sciarra F、Campolo F、Gelibter AJ、Sirgiovanni G、Cortesi E、Lenzi A
单位
Department of Experimental Medicine, Sapienza University of Rome, Viale Regina Elena 324, 00161 Rome, Italy.Italy
期刊
Cancers2023 Jul 12
原文标识
PubMed 37509255　·　DOI 10.3390/cancers15143592

在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →